Posted by Michael Wonder on 26 Sep 2022
Fintepla (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome
26 September 2022 - Nippon Shinyaku announced today that UCB Japan has obtained marketing approval from the Ministry of Health, Labour and Welfare, for Fintepla 2.2 mg/mL oral solution (fenfluramine hydrochloride) for the treatment of seizures in patients with Dravet syndrome in Japan.
